Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316478 | 0.76 | TSHR (0.39) | TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL2955010 | 0.67 | TSHR (0.37) | TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL4919141 | 0.64 | GPR84 (0.33) | TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL31590689 | 0.64 | ALDH1A1 (0.57) | TSHRKDM4EALDH1A1USP2MAPT | |
| SCHEMBL568981 | 0.64 | ALDH1A1 (0.57) | TSHRKDM4EALDH1A1USP2MAPT | |
| SCHEMBL11325428 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL7288086 | 0.63 | ALDH1A1 (0.55) | TSHRKDM4EALDH1A1USP2MAPT | |
| Bromide SCHEMBL27526906 | 0.63 | ALDH1A1 (0.55) | TSHRKDM4EALDH1A1USP2MAPT | |
| SCHEMBL8270010 | 0.63 | HDAC8 (0.42) | TSHRALDH1A1 | |
| SCHEMBL1585098 | 0.62 | AR (0.52) | TSHRKDM4EALDH1A1USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487486-B2 | Derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3, 4-dioxygenase | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160052886-A1 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2016-02-25 | — | — | US | disclosed |
| US-9260394-B2 | Derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3, 4-dioxygenase | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130289081-A1 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE | UNIVERSITA' DEGLI DI PARMA (IT) | 2013-10-31 | — | — | US | disclosed |
| WO-2012097869-A1 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3,4-DIOXYGENASE | UNIVERSITA' DEGLI STUDI DI PARMA (IT) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052886-A1 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE | HAAO, NQO2, HAO1 | TSHR 3982/4885KDM4E 2416/4885ALDH1A1 245/4885 |
| US-20130289081-A1 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE | HAAO, NQO2, HAO1 | TSHR 3982/4885KDM4E 2416/4885ALDH1A1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.